Capital Group Companies Inc Form 8.3 - Pfizer Inc. (5361G)
23 Novembro 2015 - 9:55AM
UK Regulatory
TIDMPFZ
RNS Number : 5361G
Capital Group Companies Inc
23 November 2015
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing The Capital Group Companies, Inc.
(Note 1)
============================== ===========================================
Company dealt in Pfizer Inc.
============================== ===========================================
Class of relevant security US$0.05 common stock (ISIN: US7170811035)
to which the dealings being
disclosed relate (Note
2)
============================== ===========================================
Date of dealing 20 November 2015
============================== ===========================================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
============================= ======================= ===================
Number (%) Number (%)
============================= ============== ======= =========== ======
(1) Relevant securities 123,983,539 (2.01%)
============================= ======================= ===================
(2) Derivatives (other
than options)
============================= ======================= ===================
(3) Options and agreements
to purchase/sell
============================= ======================= ===================
123,983,539*
Total (2.01%)
============================= ======================= ===================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant Long Short
security:
============================ =================== =====================
Number (%) Number (%)
============================ ========== ===== =========== ======
(1) Relevant securities
============================ =================== =====================
(2) Derivatives (other
than options)
============================ =================== =====================
(3) Options and agreements
to purchase/sell
============================ =================== =====================
Total
============================ =================== =====================
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit (Note
securities 5)
================ =========================== ==========================
Sale 105,600 USD 32.1890
================ =========================== ==========================
Sale 100,000 USD 32.2350
================ =========================== ==========================
Sale 4,160,100 USD 32.4000
================ =========================== ==========================
Sale 111,300 USD 32.4025
================ =========================== ==========================
Sale 463,400 USD 32.4140
================ =========================== ==========================
Sale 56,900 USD 32.4566
================ =========================== ==========================
(b) Derivatives transactions (other than options transactions)
Product name, Nature of Number of relevant Price per unit
e.g. CFD transaction securities (Note 5)
(Note 6) (Note 7)
============= ============ ================== ===============
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number Exercise Type, e.g. Expiry Option money
name, selling, of securities price American, date paid/received
e.g. purchasing, to which European per unit
call varying the option etc. (Note 5)
option etc. relates
(Note 7)
======= ============ ============== ======== ========== ====== ==============
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
================= =========================== ======================
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note
5)
===================== ============== ==========================
OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced. If none, this
should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 20 November 2015
============================ =================
Contact name Vivien Tan
============================ =================
Telephone number +213.615.0469
============================ =================
If a connected EFM, name n/a
of offeree/offeror with
which connected
============================ =================
If a connected EFM, state n/a
nature of connection (Note
10)
============================ =================
*20 shares due to transfer in.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISEEAEFFASPSFEF
(END) Dow Jones Newswires
November 23, 2015 06:55 ET (11:55 GMT)
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
